Isotopia Molecular Imaging News
12 articles
/PRNewswire/ -- Isotopia Molecular Imaging, in partnership with Cardirad , proudly announces the launch of Isoprotrace®—an advanced Gallium-68 Gozetotide...
Isotopia Molecular Imaging, in collaboration with Cardirad, has launched Isoprotrace®, a Gallium-68 Gozetotide preparation kit for prostate cancer imaging, in Sweden and Denmark. This product is designed to enhance the detection and management of prostate cancer through PET imaging. The launch signifies a significant expansion into the Nordic markets, providing healthcare professionals with advanced diagnostic tools. Cardirad will distribute Isoprotrace® across Sweden and Denmark, ensuring accessibility to medical facilities. The product has already received marketing authorization in the Netherlands, UK, and Germany, with plans for further expansion in the EU. This launch underscores Isotopias commitment to advancing prostate cancer care globally.
PartnersProduct Stage
/PRNewswire/ -- Isotopia, a leading developer of innovative radio-pharmaceuticals, has officially launched Isoprotrace® in Germany. DSD Pharma, a trusted...
/PRNewswire/ -- Kinectrics and Isotopia have announced a groundbreaking agreement under which Kinectrics will provide Isotopia with a reliable supply of...
Isotopia Issues a call to action to the radionuclide Therapy industry.
Isotopia Molecular Imaging, a global pharmaceutical company, is calling for urgent collaboration in the Lu-177 radiopharmaceuticals sector. The companys CEO, Dr. Eli Shalom, highlighted the current monopoly of Yb-176 production and the insufficient supply to meet growing demand. He also pointed out the close ties between research reactors and certain pharmaceutical firms, which restrict broader collaborations with various Lu-177 producers. Dr. Shalom emphasized the need for collaboration to ensure the sectors success and bolster investor confidence.
Partners
Clovis Oncology and Isotopia Announce Lutetium-177 Clinical Supply Agreement
Isotopia and CPDC Successfully Deliver First Doses of n.c.a. Lu-177 to North American Customers
Isotopia Molecular Imaging has successfully transferred its technology for the production of n.c.a. Lu-177 to CPDCs GMP facility. CPDC has shipped its first doses of commercial n.c.a. Lu-177, which is a commonly used radiometal for targeted radiotherapy. This collaboration strengthens Isotopias global footprint in the n.c.a. Lu-177 supply chain and ensures a reliable supply of medical isotopes. CPDC, a leading CDMO, aims to become an all-encompassing radiopharmaceutical CDMO. Isotopia plans to create a global footprint for efficient production of Lu-177, with manufacturing sites in Israel, North America, and Europe. The article invites readers to learn more about this milestone at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2022 annual meeting.
PartnersExpand
Isotopia and the Peter MacCallum Cancer Centre announce Terbium-161 clinical study collaboration
Isotopia Molecular Imaging Limited has signed a clinical research and supply agreement with Peter MacCallum Cancer Centre for the medical radioisotope no-carrier-added Terbium-161 (n.c.a. Tb-161), an innovative therapeutic isotope used for targeted cancer treatment. The agreement will support a first-in-human pilot study conducted by the Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC) at Peter Mac. The study will use 161Tb, a radioactive compound, linked to a small molecule targeting prostate specific membrane antigen (PSMA) to treat men with advanced prostate cancer. Isotopia aims to develop a new generation of therapeutic isotopes for targeted therapy.
Partners
Isotopia Molecular Imaging begins clinical supply collaboration with Y-mAbs Therapeutics, Inc.
Isotopia Molecular Imaging has announced a collaboration with Y-mAbs Therapeutics for the supply of the medical radioisotope no-carrier-added Lutetium-177 (n.c.a. 177Lu) to support clinical development for 177Lu-DTPA-omburtamab for the treatment of B7-H3 positive Central Nervous System and Leptomeningeal Metastasis from tumors in adult patients. Isotopia has developed a unique method to produce a highly pure form of Lu-177. The collaboration aims to improve the quality of life of cancer patients with targeted radionuclide therapies.
Partners
Isotopia Molecular Imaging and CPDC Announce Production Agreement for n.c.a. Lu-177
Isotopia Molecular Imaging and CPDC have entered into an agreement for the production and distribution of no-carrier-added Lutetium-177 (n.c.a. Lu-177), a critical medical radioisotope used in the manufacturing of radiopharmaceuticals for cancer treatment. CPDC will produce n.c.a. Lu-177 in collaboration with Isotopia for distribution in North America. Isotopias CEO stated that the partnership will enhance distribution and secure supply for their clients in North America. Isotopia and CPDC also plan to expand their partnership for commercial-scale production. The Centre for Probe Development and Commercialization (CPDC) is a global leader in radiopharmaceutical development and manufacturing. NuGeneris Specialty Pharmaceuticals Inc., a subsidiary of CPDC, will be involved in the production. The partnership aims to ensure a stable and reliable supply of medical isotopes for life-altering therapies.
PartnersExpand
Isotopia Molecular Imaging and Eckert & Ziegler to Start Partnership for Prostate Cancer Imaging
Isotopia Molecular Imaging has entered into a development partnership with Eckert & Ziegler for the development of its PSMA-11-Kit for prostate cancer imaging. The agreement includes the collaboration to make operation of the Kit feasible on E&Z´s KitLab, having E&Z´s GalliaPharm® (68Ge/68Ga generator) in the Drug Master File (DMF) of the Kit, and completion of the necessary steps to obtain marketing authorization in the EU.
Partners
Isotopia Co. and Bar-Ilan U. developing new method for diagnosis and treatment of cancer
Israeli company Isotopia is partnering with Prof. Rachela Popovtzer of Bar-Ilan University to develop a radioactive marker for cancer detection. The marker, based on nanoparticles, aims to distinguish between tumors and inflammation, addressing a common issue with current imaging methods. The research is part of the Magneton program, funded by the Innovation Authority, which encourages the transfer of academic technological knowledge to innovative industry products. Isotopias CEO, Dr. Eli Shalom, highlighted the potential of the technology to improve diagnoses and its compatibility with existing PET/CT centers.
PartnersInvestment
Metro Ontario to invest in Isotopia Molecular Imaging
Metro Ontario will invest NIS 13 million in Isotopia Molecular Imaging Ltd, a company that makes substances for use in PET scans and conducts nuclear medical research. The investment is expected to have a positive impact on the growth of the company.
Investment
